Dosing

PROTECT WITH THE ONLY 2-DOSE HEPATITIS B VACCINE AVAILABLE FOR ADULT PATIENTS1,2

The Advisory Committee on Immunization Practices (ACIP) recommends the use of HEPLISAV-B for protecting adults at risk of hepatitis B infection.2

Dotted Line with Carrot

HEPLISAV-B1

(0.5 mL each)
Month
Full Syringe Month Month 0
Full Syringe Month Month 0
95%

95% of those who received HEPLISAV-B were protected after just 2 doses in 1 month.1

VS

Engerix-B3

Month
Empty Syringe Month Month 0
Empty Syringe Month Month 1
Empty Syringe Month Month 2
Empty Syringe Month Month 3
Empty Syringe Month Month 4
Empty Syringe Month Month 5
Empty Syringe Month Month 6
81.3%

After 6 months, only 81.3% of those who received Engerix-B achieved protection.1

“The benefits of protection with 2 doses administered over 1 month make HEPLISAV-B an important option for prevention of hepatitis B.”4

MMWR Morb Mortal Wkly Rep. 2018;67(15):455-458.
See full article here
Video Thumbnail

HEPLISAV-B dosing

Dr. Robert Gish talks about HEPLISAV-B dosing and administration.

Watch full video
Syringe

Administer HEPLISAV-B by intramuscular injection in the deltoid region1

  • Available in prefilled, latex-free syringes for easy storage and administration
  • Compact packaging
  • Store in a refrigerator
  • Do not freeze
DOWNLOAD DOSING AND ADMINISTRATION GUIDE
INDICATION AND IMPORTANT SAFETY INFORMATION
INDICATION

HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

IMPORTANT SAFETY INFORMATION

Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.

Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.

The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).

Please see full Prescribing Information.

Phone IconCall 1-84-HEPLISAV (1-844-375-4728) or order online.
Call to Order
INDICATION AND IMPORTANT SAFETY INFORMATION
INDICATION

HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

IMPORTANT SAFETY INFORMATION

Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.

Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.

The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).

Please see full Prescribing Information.

References:

1. HEPLISAV-B [package insert]. Berkeley, CA: Dynavax Technologies Corporation; 2018. 2. Kim DK, Hunter P; for the Advisory Committee on Immunization Practices. Recommended adult immunization schedule, United States, 2019. Ann Intern Med. 2019;170(3):182-192. 3. Engerix-B [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2015. 4. Schillie S, Harris A, Link-Gelles R, Romero J, Ward J, Nelson N. Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis B vaccine with a novel adjuvant. MMWR Morb Mortal Wkly Rep. 2018;67(15):455-458.